SCHEDULE 13G/A: Greenhaven Road Investment Management Discloses 9.8% Stake in Lifecore Biomedical
Beneficial Ownership Report
Greenhaven Road Investment Management, along with affiliated entities, has reported a 9.8% beneficial ownership stake in Lifecore Biomedical, Inc. as of December 31, 2024.
Summary
- Greenhaven Road Investment Management, L.P., MVM Funds, LLC, and Scott Miller, along with Greenhaven Road Capital Fund 1, L.P. and Greenhaven Road Capital Fund 2, L.P., collectively reported beneficial ownership of 3,616,146 shares of Lifecore Biomedical, Inc. common stock.
- This aggregate ownership represents 9.8% of Lifecore Biomedical's outstanding common stock.
- The percentage of ownership is based on 37,025,331 shares of Common Stock outstanding as of December 26, 2024, as reported by Lifecore Biomedical in its Form 10-Q filed on January 2, 2025.
- Greenhaven Road Capital Fund 1, L.P. directly owns 1,633,634 shares, representing 4.4% of the class.
- Greenhaven Road Capital Fund 2, L.P. directly owns 1,982,512 shares, representing 5.4% of the class.
- The reporting persons, including Greenhaven Road Investment Management, MVM Funds, LLC, and Scott Miller, each hold sole voting and sole dispositive power over the shares reported.
Sentiment
Score: 5
Explanation: The document is a factual report of beneficial ownership, indicating a significant but passive investment stake. It does not contain information that would inherently sway sentiment positively or negatively regarding the issuer's performance or prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- The disclosure of a significant 9.8% ownership stake by Greenhaven Road Investment Management and its affiliates may signal increased institutional investor interest in Lifecore Biomedical, potentially influencing shareholder perception and market liquidity.
Key Dates
| Date | Description |
|---|---|
| 2024-12-26 | Date as of which 37,025,331 shares of Common Stock were outstanding, as reported by the Issuer in its Form 10-Q. |
| 2024-12-31 | Date of event which requires filing of this statement. |
| 2025-02-14 | Filing date of the Schedule 13G Amendment No. 2. |
Keywords
Lifecore Biomedical, Greenhaven Road Investment Management, SEC filing, Schedule 13G, beneficial ownership, institutional ownership, common stock, investment management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.